Camp4 Therapeutics Business Summary

Camp4 Therapeutics is a clinical-stage biopharmaceutical company that leverages its proprietary RNA Actuating Platform (RAP) to discover and develop antisense oligonucleotides (ASOs) designed to upregulate gene expression. The company’s business model is predicated on the development of a therapeutic pipeline targeting regulatory RNAs (regRNAs), generating revenue through strategic research collaborations, milestone-based licensing fees, and the long-term commercialization of its lead candidates, including CMP-135 for Dravet syndrome and CMP-125 for SYNGAP1-related encephalopathy. Camp4 operates within the high-growth precision medicine sector, specifically focusing on gene dosage restoration rather than traditional gene silencing or replacement. Its primary direct competitors include Stoke Therapeutics, which utilizes its TANGO platform for gene upregulation, as well as established RNA therapeutics leaders like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Camp4 differentiates itself by its ability to systematically map the "regRNome," allowing for the precise titration of protein production across a broad spectrum of haploinsufficient diseases. The company was co-founded by world-renowned geneticists Dr. Richard Young of the Whitehead Institute/MIT and Dr. Leonard Zon of Harvard Medical School, whose foundational research in gene control elements underpins the RAP platform. The leadership team is headed by CEO Josh Mandel-Brehm, who brings significant business development expertise from his tenure at Biogen and Sanofi Genzyme, and CSO David Bumcrot, an RNA specialist with a track record at Alnylam and Editas Medicine. Financial operations are overseen by CFO Kelly Gold, who previously held leadership roles at various venture-backed biotech firms. Camp4’s strategic direction is supported by a robust investor base including Enavate Sciences, 5AM Ventures, Polaris Partners, and Andreessen Horowitz (a16z). The Board of Directors includes notable industry veterans such as Nobel Laureate Phillip Sharp and Polaris Partners’ Amir Nashat, ensuring a high degree of scientific rigor and commercial acumen as the company progresses through clinical milestones.